The Life Sciences Greenhouses are models of effectiveness and efficiency. They capture the innovation potential of the life sciences industry and nurture that potential with critical early-stage funding and sector-specific business expertise. Pennsylvanians benefit directly as new companies are formed, jobs are created, additional capital is attracted to the Commonwealth, and life-saving technologies reach patients.
The table below highlights just a few of the breakthrough products brought to market by companies backed by the PA Life Sciences Greenhouse Initiative.
| Company | Product Name | Use | Regulatory Approval |
| Avid/Lilly | Amyvid™ | Determines presence of beta amyloid plaque in patients with cognitive impairment | FDA |
| InfraScan | InfraScanner 1000 InfraScanner 2000 | Hand held device to detect brain hematoma after head trauma | FDA |
| NuPathe | Zecuity® | Sumatriptan transdermal patch for migraine | FDA |
| Ceptaris | VALCHLOR™ (mechlorethamine) gel | Topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) | FDA |
| Indigo BioSciences | Nuclear receptor assay kits and services | Drug screening | Not Applicable |
| Maculogix | AdaptDx™ | Macular Degeneration | FDA |
| Micro Interventional Devices | Permaseal™ | Heart Valve Repair | FDA, CE Mark |
| Chromatan | Tangential Chromatography | Single-use column-free proteins and vaccines purification. | Not Applicable |
| ALung | Hemolung® RAS | Respiratory Assist System | EU |
| Complexa | CXA-10 | Fibrosis, inflammation, and renal diseases | In Process |
| Forest Devices | AlphaStroke | Stroke screening | In Process |
| Rinovum Women’s Health | Stork™ Rinovum Vitamin Line | Reproductive Health Aid | FDA |
BioAdvance Biotechnology Greenhouse
of Southeastern Pennsylvania
215.966.6214 | bioadvance.com
Life Sciences Greenhouse
of Central Pennsylvania
717.635.2100 | lsgpa.com
Pittsburgh Life Sciences
Greenhouse
412.201.7370 | plsg.com
Recent Posts
READ MORE>>
Source: BioAdvance
READ MORE>>
Source: LSGPA
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease
PLSG portfolio company Cognition Therapeutics will begin patient dosing in the SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition)..
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease globenewswire.com First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer's Disease Research Unit and Yale PET Center
1 likes, 0 comments ⋅ 14 hours ago
(more…)